Why Does Macquarie Think Syngene Shares Could Rally 67% From Current Levels?

Synopsis: Macquarie maintains an Outperform rating on Syngene International, seeing a 67% upside with a ₹735 target. It believes recent stock weakness already prices in near-term CMO issues. Growth from research, biologics, and better execution under new management, plus conservative FY27 guidance, could drive earnings upgrades and valuation re-rating.

The shares of a Small-Cap company that specialises as a global Contract Research, Development, and Manufacturing Organisation (CRDMO), providing end-to-end services to the pharmaceutical, biotechnology, animal health, and agrochemical sectors, are in focus following Macquarie’s target, with an upside potential of  67 percent.

With a market capitalization of Rs. 17,739.24 crores in the day’s trade, the shares of Syngene International Ltd rose upto 1.57 percent, making a high of Rs. 442.95 per share compared to its previous closing price of Rs. 436.10 per share.

What Happened

Syngene International Ltd, a global Contract Research, Development, and Manufacturing Organisation (CRDMO), is in the spotlight after Macquarie assigned it an Outperform rating with a target price of Rs. 735, revised down from an earlier target of Rs. 835, implying an upside potential of 67 percent from the previous closing price. Reason for the Target 

Stock Correction Has Already Priced in Near-Term Challenges

Macquarie believes the recent decline in Syngene’s share price has largely factored in concerns surrounding its Contract Manufacturing Organisation (CMO) business, particularly the impact from a single product-related headwind. As a result, downside risks appear limited, while investors may be underestimating the company’s long-term earnings potential and growth opportunities.

Market Is Overlooking Medium-Term Growth Drivers

According to Macquarie, the current valuation does not fully reflect several medium-term growth levers that can accelerate revenue and profitability over the next few years. These include expansion in research services, biologics capabilities, and manufacturing infrastructure, which position Syngene to benefit from increasing global outsourcing demand from pharmaceutical and biotech companies.

New Management Focused on Stronger Commercial Execution

The brokerage highlights that the new management team is placing greater emphasis on commercial execution and client acquisition. Improved business development efforts, better utilisation of existing assets, and a sharper focus on customer relationships can drive higher order inflows and improve revenue visibility, supporting sustainable growth.

Conservative FY27 Guidance Creates Scope for Upside

Macquarie views management’s FY27 guidance as relatively conservative. If execution improves and industry demand remains healthy, Syngene could potentially outperform these expectations. Such earnings upgrades often act as positive catalysts for stock performance, leading to valuation re-rating and stronger investor confidence.

Transition Phase Could Lead to Transformation

The brokerage describes Syngene’s current stage as moving “from transition to transformation.” While the company is navigating short-term challenges, investments made in capabilities, infrastructure, and leadership are expected to deliver benefits over the medium term. This transformation journey can strengthen competitiveness and support higher long-term shareholder returns.

Financials

The company’s revenue rose by 1.82 percent from Rs. 1,018 crores in Q4FY25 to Rs. 1,036 crores in Q4FY26. Meanwhile, Net profit declined from Rs. 183 crores to Rs. 148 crores in the same period.

The company shows a ROCE of 10.1% and ROE of 7.86%, indicating moderate returns on its capital and equity, though not very high efficiency in generating profits. Its debt-to-equity ratio of 0.09 is very low, suggesting the company operates with minimal debt and is financially conservative with a strong balance sheet and low financial risk.

As of FY2026, the company operates at a global scale with strong scientific and industry presence. It holds 400+ patents with clients and serves ~400 active clients, including 16 of the top 20 pharmaceutical companies. Its infrastructure spans international campuses in Bengaluru, Hyderabad, and Mangaluru in India, as well as Baltimore in the USA, designed to meet global standards.

Financially, the company reported revenue from operations of Rs. 3,739 crore (about US$419 million) in FY26, with a profit after tax (PAT) of Rs. 380 crore. The organisation employs 8,373 people, including 5,778 scientists, highlighting its research-heavy workforce.

Syngene International Ltd is a leading integrated contract research, development, and manufacturing organisation (CRDMO) based in Bengaluru, India. It operates as part of the Biocon Group and supports global pharmaceutical, biotechnology, and agrochemical companies in drug discovery, development, and production. The company provides end-to-end services, including early-stage research, clinical development support, and commercial-scale manufacturing.

It works with a wide range of global clients, including major pharma innovators, helping accelerate drug discovery pipelines through dedicated research facilities and scientific expertise. Its capabilities span small molecules, biologics, and complex chemistry services, making it a key outsourcing partner in the life sciences industry.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Why Does Macquarie Think Syngene Shares Could Rally 67% From Current Levels? appeared first on Trade Brains.